Our story.
Vexev founders, John Carroll (left) & Eamonn Colley (right).
We started in 2014 as two PhD students curious about the power of computational fluid dynamics to detect vascular disease.
We knew there was huge potential. But once we were in the clinic, we soon realised that our diagnosis approach needed more than just software and AI.
It needed to be turned on its head.
Today, vascular disease is treated reactively, usually once someone is already showing symptoms (read: having a heart attack, stroke, or developing gangrene).
Why? Current imaging technologies are inadequate. While CT & MRI give accurate anatomical information, they can be dangerous and expensive, and miss important blood flow information. Ultrasound, on the other hand, is non-invasive, more affordable, and captures flow information; but it can be inconsistent and relies on highly skilled practitioners.
None of the current imaging systems have the right combination of accessibility, safety, diagnostic power, and consistency needed to regularly monitor for disease before it’s too late.
This is why we currently wait for the symptoms before performing any imaging.
We believe that a proactive monitoring approach has the power to save lives.
We created an ultrasound-powered imaging robot and software platform: to automatically take fast and consistent 3D scans, to supercharge the diagnostic power of vascular clinicians, with the simple push of a button.
We brought on a team including former F1 engineers to design the hardware and model the complex blood flows.
We secured preseed and seed funding from Australia’s leading VC, Blackbird Ventures. And we’re working with some of Australia’s pre-eminent clinicians to refine our technology.